A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 prospective, randomized, placebo-controlled, double-blinded, parallel
group, single administration, multi-center study to assess the safety and efficacy of
efineptakin alfa single treatment compared to placebo in elderly participants (adults
≥50years) with asymptomatic or mild COVID-19